Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression
2021
Ashrafizadeh, Milad | Mirzaei, Sepideh | Gholami, Mohammad Hossein | Hashemi, Farid | Zabolian, Amirhossein | Raei, Mehdi | Hushmandi, Kiavash | Z̤arrābī, ʻAlī | Voelcker, Nicolas H. | Aref, Amir Reza | Hamblin, Michael R. | Varma, Rajender S. | Samarghandian, Saeed | Arostegi, I.J. | Alzola, M. | Kumar, Alan Prem | Thakur, Vijay Kumar | Nabavi, Noushin | Makvandi, Pooyan | Tay, Franklin R. | Orive, Gorka
An important motivation for the use of nanomaterials and nanoarchitectures in cancer therapy emanates from the widespread emergence of drug resistance. Although doxorubicin (DOX) induces cell cycle arrest and DNA damage by suppressing topoisomerase activity, resistance to DOX has severely restricted its anti-cancer potential. Hyaluronic acid (HA) has been extensively utilized for synthesizing nanoparticles as it interacts with CD44 expressed on the surface of cancer cells. Cancer cells can take up HA-modified nanoparticles through receptor-mediated endocytosis. Various types of nanostructures such as carbon nanomaterials, lipid nanoparticles and polymeric nanocarriers have been modified with HA to enhance the delivery of DOX to cancer cells. Hyaluronic acid-based advanced materials provide a platform for the co-delivery of genes and drugs along with DOX to enhance the efficacy of anti-cancer therapy and overcome chemoresistance. In the present review, the potential methods and application of HA-modified nanostructures for DOX delivery in anti-cancer therapy are discussed.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by National Agricultural Library